That means, if Harry were a real-life patient, there’d be reason to believe his disease was advanced. “It could still be local”—which means it hasn’t yet spread beyond the prostate—“but it would take ...

In reality, most prostate cancers are detected through routine screening, typically with a simple blood test. Experts ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Low-grade serous ovarian cancer (LGSC), accounts for just 5% to 10% of all epithelial ovarian cancers, but its distinct ...

There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive ...

BCG therapy—the gold standard treatment for non-muscle invasive bladder cancer (NMIBC), where the cancer has not penetrated ...

Bladder cancer, often misunderstood, affects both men and women, not just the elderly. While smoking is a significant risk ...

Cancer is the leading cause of premature death in North America. An estimated 2.1 million new cancer cases and 701,000 cancer deaths occur in North America each year. The region contributes almost ...

(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma oral abstract session and a presentation by Dr. Jeannie Hoffman-Censits discussing an interim analysis from the JAVELIN ...

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...